UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
|
☒ |
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2020
OR
|
☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ___________________ to ___________________
Commission File Number: 001-39401
iTeos Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware |
|
84-3365066 |
|
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer |
|
139 Main Street Cambridge, MA |
|
02142 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (339) 217 0161
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
Common stock, $0.001 par value per share |
|
ITOS |
|
Nasdaq Global Market |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer |
|
☐ |
|
Accelerated filer |
|
☐ |
|
|
|
|
|
|
|
|
|
Non-accelerated filer |
|
☒ |
|
Smaller reporting company |
|
☒ |
|
|
|
|
|
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of October 31, 2020, the registrant had 35,044,758 shares of common stock, $0.001 par value per share, outstanding.
Summary of the material risks associated with our business
Our business is subject to numerous risks and uncertainties that you should be aware of before making an investment decision, including those highlighted in the section entitled “Risk Factors”. These risks include, but are not limited to, the following:
|
|
• |
We will not be able to commercialize our current product candidates and any future product candidates if our preclinical studies do not produce successful results or our clinical trials do not demonstrate the safety and efficacy of our current or future product candidates. |
|
|
• |
As an organization, we have never conducted pivotal clinical trials, and we may be unable to do so for any product candidates we may develop. |
|
|
• |
Positive results from early preclinical studies of our product candidates are not necessarily predictive of the results of later preclinical studies and any future clinical trials of our product candidates. If we cannot replicate the positive results from our earlier preclinical studies of our product candidates in our later preclinical studies and future clinical trials, we may be unable to successfully develop, obtain regulatory for and commercialize our product candidates. |
|
|
• |
We may not be able to file INDs or IND amendments to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA or a comparable foreign regulatory may not permit us to proceed. |
|
|
• |
We face significant competition from other biopharmaceutical and biotechnology companies, academic institutions, government agencies, and other research organizations, which may result in others discovering, developing or commercializing products more quickly or marketing them more successfully than us. If their product candidates are shown to be safer or more effective than ours, our commercial opportunity may be reduced or eliminated. |
|
|
• |
We rely on third parties to conduct our clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects. |
|
|
• |
Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. We have never generated any revenue from product sales and may never be profitable. |
|
|
• |
If the current public health pandemic related to coronavirus (COVID-19) continues to worsen, our operations, business and financial results may be adversely impacted. |
|
|
• |
If we are unable to obtain and maintain sufficient intellectual property protection for our current product candidates or any future product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected. |
|
|
• |
Even if our development efforts are successful, we may not obtain regulatory approval for any of our current product candidates or any future product candidates in the United States or other jurisdictions, which would prevent us from commercializing our current product candidates and any future product candidates. Even if we obtain regulatory approval for our current product candidates and any future product candidates, any such approval may be subject to limitations, including with respect to the approved indications or patient populations, which could impair our ability to successfully commercialize our current product candidates or any future product candidates. |
|
|
• |
We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. |
|
|
• |
We may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure. |
|
|
• |
We are an emerging growth company and a smaller reporting company, and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors. |
|
|
• |
The trading price of our common stock may be volatile. We may be at an increased risk of securities class action litigation. |
i
The summary risk factors described above should be read together with the text of the full risk factors below, in the section entitled “Risk Factors” and the other information set forth in this Quarterly Report on 10-Q, including our condensed consolidated financial statements and the related notes, as well as in other documents that we file with the Securities and Exchange Commission (SEC). The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us, or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations and future growth prospects.
ii
|
|
|
Page |
|
PART I. |
1 |
|
|
Item 1. |
1 |
|
|
|
1 |
|
|
|
Condensed Consolidated Statements of Operations and Comprehensive Loss |
2 |
|
|
3 |
|
|
|
4 |
|
|
|
Notes to Unaudited Condensed Consolidated Financial Statements |
5 |
|
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
17 |
|
Item 3. |
29 |
|
|
Item 4. |
30 |
|
|
PART II. |
31 |
|
|
Item 1. |
31 |
|
|
Item 1A. |
31 |
|
|
Item 2. |
84 |
|
|
Item 3. |
84 |
|
|
Item 4. |
84 |
|
|
Item 5. |
84 |
|
|
Item 6. |
85 |
|
|
87 |
||
iii
iTeos Therapeutics, Inc. and subsidiaries
Condensed consolidated balance sheets
(unaudited)
|
(in thousands, except share amounts) |
|
September 30, 2020 |
|
|
December 31, 2019 |
|
||
|
Assets |
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
339,981 |
|
|
$ |
19,868 |
|
|
Grants receivable |
|
|
2,307 |
|
|
|
5,196 |
|
|
Research and development tax credits receivable |
|
|
184 |
|
|
|
133 |
|
|
Prepaid expenses and other current assets |
|
|
3,262 |
|
|
|
879 |
|
|
Total current assets |
|
|
345,734 |
|
|
|
26,076 |
|
|
Property and equipment, net |
|
|
1,287 |
|
|
|
1,336 |
|
|
Research and development tax credits receivable |
|
|
3,536 |
|
|
|
2,917 |
|
|
Restricted cash |
|
|
126 |
|
|
|
122 |
|
|
Other assets |
|
|
261 |
|
|
|
293 |
|
|
Total assets |
|
$ |
350,944 |
|
|
$ |
30,744 |
|
|
Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
2,409 |
|
|
$ |
1,174 |
|
|
Accrued expenses and other current liabilities |
|
|
6,054 |
|
|
|
4,262 |
|
|
Preferred stock tranche rights liability |
|
|
— |
|
|
|
5,400 |
|
|
Deferred income |
|
|
1,862 |
|
|
|
2,360 |
|
|
Total current liabilities |
|
|
10,325 |
|
|
|
13,196 |
|
|
Grants repayable |
|
|
4,488 |
|
|
|
1,397 |
|
|
Other noncurrent liabilities |
|
|
505 |
|
|
|
482 |
|
|
Total liabilities |
|
|
15,318 |
|
|
|
15,075 |
|
|
Commitments and contingencies (Note 9) |
|
|
|
|
|
|
|
|
|
Redeemable convertible preferred stock |
|
|
— |
|
|
|
51,757 |
|
|
Stockholders’ equity (deficit): |
|
|
|
|
|
|
|
|
|
Preferred stock, $0.001 par value; 10,000,000 and no shares authorized at September 30, 2020 and December 31, 2019, respectively, and no shares issued or outstanding at September 30, 2020 and December 31, 2019 |
|
|
— |
|
|
|
— |
|
|
Common stock, $0.001 par value, 150,000,000 and 50,000,000 shares authorized at September 30, 2020 and December 31, 2019, respectively; 35,044,758 and 256,548 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively |
|
|
35 |
|
|
|
1 |
|
|
Additional paid-in capital |
|
|
394,488 |
|
|
|
— |
|
|
Accumulated other comprehensive loss |
|
|
97 |
|
|
|
(224 |
) |
|
Accumulated deficit |
|
|
(58,994 |
) |
|
|
(35,865 |
) |
|
Total stockholders’ equity (deficit) |
|
|
335,626 |
|
|
|
(36,088 |
) |
|
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) |
|
$ |
350,944 |
|
|
$ |
30,744 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
1
iTeos Therapeutics, Inc. and subsidiaries
Condensed consolidated statements of operations and comprehensive loss
(unaudited)
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
(in thousands, except share and per share amounts) |
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
||||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expenses |
|
$ |
8,726 |
|
|
$ |
4,998 |
|
|
$ |
20,688 |
|
|
$ |
13,251 |
|
|
General and administrative expenses |
|
|
4,799 |
|
|
|
2,699 |
|
|
|
9,611 |
|
|
|
6,561 |
|
|
Total operating expenses |
|
|
13,525 |
|
|
|
7,697 |
|
|
|
30,299 |
|
|
|
19,812 |
|
|
Loss from operations |
|
|
(13,525 |
) |
|
|
(7,697 |
) |
|
|
(30,299 |
) |
|
|
(19,812 |
) |
|
Other income and expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grant income |
|
|
2,299 |
|
|
|
851 |
|
|
|
4,969 |
|
|
|
2,293 |
|
|
Fair value adjustment for Preferred Stock tranche rights liability and anti-dilution warrants liability |
|
|
— |
|
|
|
(230 |
) |
|
|
1,265 |
|
|
|
66 |
|
|
Research and development tax credits |
|
|
273 |
|
|
|
186 |
|
|
|
643 |
|
|
|
539 |
|
|
Other income (expense), net |
|
|
265 |
|
|
|
(2 |
) |
|
|
235 |
|
|
|
(77 |
) |
|
Loss before income taxes |
|
|
(10,688 |
) |
|
|
(6,892 |
) |
|
|
(23,187 |
) |
|
|
(16,991 |
) |
|
Income tax benefit (expense) |
|
|
8 |
|
|
|
(29 |
) |
|
|
58 |
|
|
|
(87 |
) |
|
Net loss |
|
|
(10,680 |
) |
|
|
(6,921 |
) |
|
|
(23,129 |
) |
|
|
(17,078 |
) |
|
Cumulative dividends on Series A preferred stock |
|
|
(36 |
) |
|
|
(107 |
) |
|
|
(249 |
) |
|
|
(320 |
) |
|
Accretion of redeemable convertible preferred stock to redemption value |
|
|
(931 |
) |
|
|
(963 |
) |
|
|
(5,120 |
) |
|
|
(2,575 |
) |
|
Net loss attributable to common stockholders |
|
$ |
(11,647 |
) |
|
$ |
(7,991 |
) |
|
$ |
(28,498 |
) |
|
$ |
(19,973 |
) |
|
Basic and diluted net loss per common share |
|
$ |
(0.48 |
) |
|
$ |
(43.03 |
) |
|
$ |
(3.40 |
) |
|
$ |
(107.55 |
) |
|
Weighted-average common shares outstanding—basic and diluted |
|
|
24,349,222 |
|
|
|
185,716 |
|
|
|
8,376,860 |
|
|
|
185,716 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(10,680 |
) |
|
$ |
(6,921 |
) |
|
$ |
(23,129 |
) |
|
$ |
(17,078 |
) |
|
Foreign currency translation adjustments |
|
|
393 |
|
|
|
(1,090 |
) |
|
|
321 |
|
|
|
(828 |
) |
|
Comprehensive loss |
|
$ |
(10,287 |
) |
|
$ |
(8,011 |
) |
|
$ |
(22,808 |
) |
|
$ |
(17,906 |
) |
The accompanying notes are an integral part of these condensed consolidated financial statements.
2
iTeos Therapeutics, Inc. and subsidiaries
Condensed consolidated statements of redeemable convertible preferred stock and stockholders’ equity/deficit
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
Total |
|
||||||||||||||||||||||
|
|
|
Series A |
|
|
Series B |
|
|
|
|
|
|
|
Profit |
|
|
Additional |
|
|
other |
|
|
|
|
|
|
stockholders’ |
|
|||||||||||||||||||||||
|
In thousands except share amounts |
|
preferred stock |
|
|
preferred stock |
|
|
Common stock |
|
|
|
|
certificates |
|
|
paid-in |
|
|
comprehensive |
|
|
Accumulated |
|
|
equity/ |
|
||||||||||||||||||||||||
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
|
|
Shares |
|
|
Amount |
|
|
capital |
|
|
income (loss) |
|
|
deficit |
|
|
(deficit) |
|
||||||||||||
|
Balance at December 31, 2018 |
|
|
6,167,726 |
|
|
$ |
5,353 |
|
|
|
10,900,376 |
|
|
$ |
20,378 |
|
|
|
185,716 |
|
|
$ |
87 |
|
|
|
|
|
7,022 |
|
|
$ |
11 |
|
|
$ |
— |
|
|
$ |
(11 |
) |
|
$ |
(10,765 |
) |
|
$ |
(10,678 |
) |
|
Accretion of Series B Preferred Stock to redemption value |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
697 |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
(205 |
) |
|
|
— |
|
|
|
(492 |
) |
|
|
(697 |
) |
|
Stock-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
205 |
|
|
|
— |
|
|
|
— |
|
|
|
205 |
|
|
Currency translation adjustment |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(267 |
) |
|
|
— |
|
|
|
(267 |
) |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(4,402 |
) |
|
|
(4,402 |
) |
|
Balance at March 31, 2019 |
|
|
6,167,726 |
|
|
|
5,353 |
|
|
|
10,900,376 |
|
|
|
21,075 |
|
|
|
185,716 |
|
|
|
87 |
|
|
|
|
|
7,022 |
|
|
|
11 |
|
|
|
- |
|
|
|
(278 |
) |
|
|
(15,659 |
) |
|
|
(15,839 |
) |
|
Issuance of Series B Preferred Stock |
|
|
— |
|
|
|
- |
|
|
|
10,042,405 |
|
|
|
22,372 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accretion of Series B Preferred Stock to redemption value |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
915 |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
(203 |
) |
|
|
— |
|
|
|
(712 |
) |
|
|
(915 |
) |
|
Exercise of stock options into profit certificates |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
63,810 |
|
|
|
102 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
102 |
|
|
Stock-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
203 |
|
|
|
— |
|
|
|
— |
|
|
|
203 |
|
|
Currency translation adjustment |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
529 |
|
|
|
— |
|
|
|
529 |
|
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(5,755 |
) |
|
|
(5,755 |
) |
|
Balance at June 30, 2019 |
|
|
6,167,726 |
|
|
|
5,353 |
|
|
|
20,942,781 |
|
|
|
44,362 |
|
|
|
185,716 |
|
|
|
87 |
|
|
|
|
|
70,832 |
|
|
|
113 |
|
|
|
— |
|
|
|
251 |
|
|
|
(22,126 |
) |
|
|
(21,675 |
) |
|
Accretion of Series B Preferred Stock to redemption value |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
963 |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
(201 |
) |
|
|
— |
|
|
|
(762 |
) |
|
|
(963 |
) |
|
Stock-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
201 |
|
|
|
— |
|
|
|
— |
|
|
|
201 |
|
|
Currency translation adjustment |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,090 |
) |
|
|
— |
|
|
|
(1,090 |
) |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
(6,921 |
) |
|
|
(6,921 |
) |
|
Balance at September 30, 2019 |
|
|
6,167,726 |
|
|
$ |
5,353 |
|
|
|
20,942,781 |
|
|
$ |
45,325 |
|
|
|
185,716 |
|
|
$ |
87 |
|
|
# |
|
|
70,832 |
|
|
$ |
113 |
|
|
$ |
— |
|
|
$ |
(839 |
) |
|
$ |
(29,809 |
) |
|
$ |
(30,448 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
Total |
|
||
|
|
|
Series A |
|
|
Series B |
|
|
|
|
|
Profit |
|
|
Additional |
|
|
other |
|
|
|
|
|
|
stockholders’ |
|
|||||||||||||||||||||||
|
In thousands except share amounts |
|
preferred stock |
|
|
preferred stock |
|
|
Common stock |
|
|
certificates |
|
|
paid-in |
|
|
comprehensive |
|
|
Accumulated |
|
|
equity/ |
|
||||||||||||||||||||||||
|
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
Shares |
|
|
Amount |
|
|
capital |
|
|
income (loss) |
|
|
deficit |
|
|
(deficit) |
|
||||||||||||
|
Balance at December 31, 2019 |
|
|
6,167,726 |
|
|
$ |
5,353 |
|
|
|
20,942,781 |
|
|
$ |
46,404 |
|
|
|
256,548 |
|
|
$ |
1 |
|
|
|
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
(224 |
) |
|
$ |
(35,865 |
) |
|
$ |
(36,088 |
) |
|
Issuance of Series B-2 Preferred Stock, net of issuance costs of $332 |
|
|
— |
|
|
|
— |
|
|
|
44,453,477 |
|
|
|
125,026 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
Settlement of preferred stock tranche right |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
4,135 |
|
|
|
— |
|
|
|
— |
|
|
|
4,135 |
|
|
Accretion of Series B and B-2 preferred stock to redemption value |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,195 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,195 |
) |
|
|
— |
|
|
|
— |
|
|
|
(1,195 |
) |
|
Stock-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
186 |
|
|
|
— |
|
|
|
— |
|
|
|
186 |
|
|
Currency translation adjustment |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(317 |
) |
|
|
— |
|
|
|
(317 |
) |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(5,247 |
) |
|
|
(5,247 |
) |
|
Balance at March 31, 2020 |
|
|
6,167,726 |
|
|
|
5,353 |
|
|
|
65,396,258 |
|
|
|
172,625 |
|
|
|
256,548 |
|
|
|
1 |
|
|
|
— |
|
|
|
— |
|
|
|
3,126 |
|
|
|
(541 |
) |
|
|
(41,112 |
) |
|
|
(38,526 |
) |
|
Accretion of Series B and B-2 preferred stock to redemption value |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
2,994 |
|
|
|
|
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(2,994 |
) |
|
|
— |
|
|
|
— |
|
|
|
(2,994 |
) |
|
Exercise of stock options into common stock |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
131,867 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
205 |
|
|
|
— |
|
|
|
— |
|
|
|
205 |
|
|
Stock-based compensation |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
350 |
|
|
|
— |
|
|
|
— |
|
|
|
350 |
|
|
Currency translation adjustment |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
245 |
|
|
|
— |
|
|
|
245 |
|
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
||||||||||||||||||||||||||